Trulicity Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The trulicity market size has grown strongly in recent years. It will grow from $7.98 million in 2025 to $8.7 million in 2026 at a compound annual growth rate (CAGR) of 9%. The growth in the historic period can be attributed to rising type 2 diabetes prevalence, limitations of oral antidiabetics, proven efficacy of glp-1 therapies, physician prescribing trends, patient adherence challenges.

The trulicity market size is expected to see strong growth in the next few years. It will grow to $12.15 million in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to growth in obesity related diabetes, expanding glp-1 indications, improved reimbursement access, increasing lifestyle disease burden, broader primary care adoption. Major trends in the forecast period include growing adoption of glp-1 receptor agonists, shift toward once weekly diabetes therapies, integration of weight management in diabetes care, expansion of cardiovascular risk reduction focus, increasing patient preference for injectable convenience.

The growing diabetes population is expected to drive the Trulicity market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels due to the body’s inability to produce insulin effectively or use it properly. Poorly managed diabetes can lead to serious complications. The rise in diabetes cases is linked to factors such as urbanization, unhealthy diets, lack of physical activity, and genetic predisposition. This increasing prevalence is fueling demand for effective treatments like Trulicity, which helps regulate blood sugar levels and improve patient outcomes. For example, in March 2024, the UK’s Office for Health Improvement and Disparities reported that in March 2023, 43.8% of people with type 1 diabetes in England received all 8 recommended care processes at GP practices participating in the NDA, up from 35.2% in 2022. As a result, the expanding diabetes population is supporting the growth of the Trulicity market.

Rising healthcare expenditures are also anticipated to propel the Trulicity market forward. Healthcare expenditures encompass total spending on medical services, prescription drugs, hospital care, and other health-related goods and services by governments, private insurers, and individuals. The increase in spending is driven by aging populations and the higher prevalence of chronic diseases, which require ongoing treatment and pharmaceutical care. Greater healthcare investment directly boosts demand for effective diabetes medications such as Trulicity, as healthcare systems and patients allocate more resources toward managing type 2 diabetes and preventing cardiovascular complications. For instance, in February 2025, the US National Center for Science and Engineering Statistics (NCSES) reported that U.S. research and development expenditures rose from $892 billion in 2022 to $940 billion in 2023, an increase of $48 billion. Consequently, rising healthcare expenditures are contributing to the growth of the Trulicity market.

Key players in the Trulicity market are emphasizing strategic investments, such as biologics production facilities, to gain a competitive edge and meet rising demand. Biologics production facilities are specialized plants designed to manufacture complex therapies derived from living organisms, including monoclonal antibodies, vaccines, and cell and gene therapies. For instance, in January 2023, Eli Lilly and Company, a US-based pharmaceutical firm, invested $450 million to expand its North Carolina plant, increasing production of Trulicity. This expansion is part of a larger $1.7 billion investment in the facility, with production expected to begin later this year and full completion by 2027, creating 100 additional jobs. Additionally, Lilly is constructing two new facilities in Indiana and investing €400 million in biologics production in Ireland. Overall, the company plans to invest $2.5 billion in manufacturing capacity over the coming years to support rising demand and upcoming product launches.

Major companies operating in the trulicity market are Eli Lilly And Company, Novo Nordisk.

North America was the largest region in the trulicity market in 2025. The regions covered in the trulicity market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the trulicity market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the trulicity market by increasing costs of imported active pharmaceutical ingredients, injection devices, and cold chain logistics. These impacts influence pricing across hospital and retail pharmacy channels. Regions such as north america and europe face moderate margin pressure due to biologic supply dependencies. At the same time, tariffs are encouraging localized manufacturing and device sourcing. This supports long-term cost optimization and supply reliability.

The trulicity market research report is one of a series of new reports that provides trulicity market statistics, including trulicity industry global market size, regional shares, competitors with a trulicity market share, detailed trulicity market segments, market trends and opportunities, and any further data you may need to thrive in the trulicity industry. This trulicity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Trulicity is a prescription medication containing dulaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. It is used to improve blood sugar control in adults with type 2 diabetes, often alongside other treatments. Administered as a once-weekly injection, it may also support weight loss and reduce the risk of cardiovascular events.

The main forms of Trulicity are prefilled syringe packages and vial packages. A prefilled syringe package is a medical container holding a single dose of medication already filled by the manufacturer. This ensures precise dosing, minimizes the risk of contamination, and offers convenience for both healthcare providers and patients. It is used in type 2 diabetes management, glycemic control, weight management, and cardiovascular risk reduction, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The trulicity market consists of sales of trulicity (Dulaglutide) injection, trulicity 3 mg and 4.5 mg, and trulicity (Dulaglutide) 0.75 mg and 1.5 mg. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.